Arbutus Biopharma Corp (ABUS)
2.75
0.00 (0.00%)
USD |
NASDAQ |
Apr 24, 16:00
2.74
-0.01
(-0.36%)
Pre-Market: 20:00
Arbutus Biopharma Net Income (TTM): -72.85M for Dec. 31, 2023
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -72.85M |
| September 30, 2023 | -75.47M |
| June 30, 2023 | -72.93M |
| March 31, 2023 | -70.03M |
| December 31, 2022 | -69.46M |
| September 30, 2022 | -68.84M |
| June 30, 2022 | -70.44M |
| March 31, 2022 | -75.63M |
| December 31, 2021 | -76.25M |
| September 30, 2021 | -71.97M |
| June 30, 2021 | -71.56M |
| March 31, 2021 | -66.26M |
| December 31, 2020 | -63.74M |
| September 30, 2020 | -71.36M |
| June 30, 2020 | -135.10M |
| March 31, 2020 | -144.33M |
| December 31, 2019 | -153.72M |
| September 30, 2019 | -147.32M |
| June 30, 2019 | -89.29M |
| March 31, 2019 | -62.88M |
| December 31, 2018 | -57.06M |
| September 30, 2018 | -74.74M |
| June 30, 2018 | -61.87M |
| March 31, 2018 | -83.22M |
| December 31, 2017 | -84.41M |
| Date | Value |
|---|---|
| September 30, 2017 | -267.18M |
| June 30, 2017 | -275.17M |
| March 31, 2017 | -386.92M |
| December 31, 2016 | -384.16M |
| September 30, 2016 | -172.33M |
| June 30, 2016 | -181.72M |
| March 31, 2016 | -66.60M |
| December 31, 2015 | -62.72M |
| September 30, 2015 | -62.02M |
| June 30, 2015 | -41.65M |
| March 31, 2015 | -32.84M |
| December 31, 2014 | -38.84M |
| September 30, 2014 | -35.27M |
| June 30, 2014 | -32.57M |
| March 31, 2014 | -29.50M |
| December 31, 2013 | -14.06M |
| September 30, 2013 | 26.80M |
| June 30, 2013 | 29.22M |
| March 31, 2013 | 30.34M |
| December 31, 2012 | 29.72M |
| September 30, 2012 | -10.83M |
| June 30, 2012 | -8.753M |
| March 31, 2012 | -10.51M |
| December 31, 2011 | -10.53M |
| September 30, 2011 | -10.44M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-153.72M
Minimum
Dec 2019
-63.74M
Maximum
Dec 2020
-87.71M
Average
-72.85M
Median
Dec 2023
Net Income (TTM) Benchmarks
| Moderna Inc | -4.714B |
| Pacira BioSciences Inc | 41.96M |
| Chimerix Inc | -82.10M |
| Karyopharm Therapeutics Inc | -143.10M |
| Corvus Pharmaceuticals Inc | -27.03M |